




The end of river blindness is in sight

Moxidectin is a new treatment for river blindness. It kills baby worms, reduces the potential for transmission, and can facilitate accelerated disease control and elimination.

Global impact of neglected tropical diseases

1b+



people suffer from neglected tropical diseases worldwide



2b



people do not have access to essential medicines¹

The burden of river blindness

20m

people are infected²

200m

more are at risk³

15.75m

suffer skin disease or vision loss as a result of infection³

River blindness is a devastating disease.

River blindness has far reaching, damaging effects on the health, social and economic capacity of affected communities.

It is a parasitic worm infection spread by the bite of a black fly. The parasite infects humans through their skin and quickly establishes and multiplies. Once a person is infected, they can develop severe itching, disfiguring skin changes and even blindness.

Despite longstanding efforts to eliminate river blindness, many regions continue to experience continuous transmission of the disease, and achieving elimination remains challenging.



Momentum: the first moxidectin implementation project

Moxidectin is a new medicine for river blindness.

In 2025, the Ghana Health Service, in partnership with MDGH, launched the Momentum Project, the first-ever community-based Mass Drug Administration (MDA) of moxidectin in Ghana.


The roll-out of moxidectin in Ghana marks the culmination of more than 25 years of work in developing moxidectin for the treatment of river blindness, initiated by the UNICEF/ UNDP/ World Bank/ WHO Special Programme for Research and Training in Tropical Disease (TDR) and Wyeth Pharmaceuticals in the 1990s.

Countries and partners are discussing the potential role of moxidectin to support their onchocerciasis elimination efforts.

A new tool for eliminating river blindness

Moxidectin is the first new medicine for river blindness approved in over 30 years.

Timeline of the Momentum project in Ghana



*MDA: Mass Drug Administration
*Mox: moxidectin




An effective and long lasting treatment

It results in complete clearance of microfilariae in more people for much longer and is well tolerated.^{4,5,6}



Reduced transmission

Continuous low or no microfilariae in the skin between treatments is expected to reduce and help prevent disease transmission and establishment of new infections.



Faster progress towards elimination

Modelling indicates that moxidectin treatment strategies are likely to reduce time to elimination of the disease and lower program implementation costs.^{7,8}



Towards better health in communities

Reducing the burden of disease will lead to healthier and more productive lives.



Medicines Development for Global Health

Medicines Development for Global Health is a not-for-profit pharmaceutical company. Its mission is to address health inequity by researching, developing and providing access to new and improved medicines for neglected diseases that disproportionately affect those in low- and middle-income countries.

If you would like to partner with us and help advance our work to improve lives in affected communities, and build a fairer, healthier and more prosperous world, please speak with us:

Barbara Roth

Principal Manager, Medicines Access
broth@mdgh.com

George Rugarabamu

Principal Manager, Corporate Development
grugarabamu@mdgh.com

Emily McCaffrey

Head of Philanthropy
emccaffrey@mdgh.com

medicinesdevelopment.com

-
1. World Health Organization. 2017. Ten Years in Public Health, 2007-2017 – Report by Dr Margaret Chan, Director-General – Access to Medicines: Making Market Forces Serve the Poor [Online]. Geneva, Switzerland: World Health Organization <https://www.who.int/publications/i/item/9789241512442>.
 2. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2021 (GBD 2021). Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2024.
 - 33 World Health Organization (WHO). Onchocerciasis fact sheet. 2025. Available from <https://www.who.int/news-room/fact-sheets/detail/onchocerciasis>
 4. Opoku et al. 2018 The Lancet. [https://doi.org/10.1016/S0140-6736\(17\)32844-1](https://doi.org/10.1016/S0140-6736(17)32844-1).
 5. US FDA prescribing information.
 6. Ghana FDA prescribing information.
 7. Kura et al. 2023. Philosophical Transactions of the Royal Society B. <https://doi.org/10.1098/rstb.2022.0277>
 8. Turner et al. 2024. Clinical Infectious Diseases, <https://doi.org/10.1093/cid/ciae054>

Thanks to Project Partners:



For important safety information visit: medicinesdevelopment.com/moxidectin

